Stem cells injected into brain to fight Parkinson's

NCT ID NCT05635409

Ongoing Disease control Sponsor: Region Skane Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This first-in-human trial tests a stem cell therapy called STEM-PD for Parkinson's disease. Eight participants with moderate Parkinson's will have dopamine-producing cells transplanted into a brain region affected by the disease. The main goal is to check safety over 12 months, with follow-up for 3 years. Researchers also look for early signs that the treatment might improve symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STEM-PD product (dopaminergic progenitor cells from human embryonic stem cells)
What this could lead to: If it works, this could point toward a treatment that repairs damaged brain cells in Parkinson's disease, potentially reducing the need for daily medication.
What could go wrong: This is a very early, small trial (8 people) focused on safety, not effectiveness. The stem cells may not survive or could cause side effects like brain swelling or abnormal growths.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Cambridge University Hospitals NHS Foundation Trust

Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom
Region Skåne - Skåne University Hospital

Lund, 214 28, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.